Search Results
Aug 18, 2025, 06:21 ET KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
has also successfully established its internationally renowned proprietary ADC development platform, OptiDCTM, with 1 ADC project approved for market launch, 1 ADC project at the NDA stage, and several ADC or novel ADC projects in clinical or preclinical development. For more information, please
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Aug 18, 2025, 06:00 ET IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025
of the company's progress to date, including presentation of new clinical data on darovasertib in neoadjuvant uveal melanoma (UM), IDE849 (DLL3 TOP1 ADC) and IDE397 (MAT2A), and outline key areas of focus as part of their future growth strategy. Details of the R&D Day agenda are below. Agenda
More news about: IDEAYA Biosciences, Inc.
Aug 18, 2025, 06:00 ET Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Iza-bren is a potential first-in-class bispecific antibody-drug conjugate (ADC) which targets both epidermal growth factor receptor and human epidermal growth factor receptor 3 (EGFRxHER3) with a topoisomerase 1 inhibitor payload.
More news about: SystImmune, Inc.
Aug 18, 2025, 05:55 ET 科倫博泰宣佈2025年中期業績
代偶聯技術及多樣化資產，致力為全球患者提供創新治療方案，為改善全球醫療健康貢獻力量。 ADC 領域全球領跑，臨床突破重塑治療格局 sac-TMT(蘆康沙妥珠單抗，SKB264/MK-2870，佳泰莱®) 全球首個獲批肺癌適應症的TROP2 ADC TNBC：已獲國家藥監局批准治療既往至少接受過2種系統治療的不可切除的局部晚期或轉移性TNBC成人患者。公司已啟動sac-TMT對比研究者選擇的化療一線治療不可手術切除的復發或轉移性TNBC患者的3期註冊性研究。
More news about: 四川科倫博泰生物醫藥股份有限公司
Aug 15, 2025, 03:29 ET 微控制器D Forum 2025科技創新論壇｜AT32 MCU串聯智慧生態，啟航「芯」未來
SRAMAES/TRNG、3×CAN(FD)、QSPI、SDRAM、EMAC適用於掃地機器人、充電樁、PLC、IoT 閘道與車載娛樂系統多元應用場景全面布局 論壇現場同步展示 AT32 MCU 多項創新應用，包括： 馬達控制：E-Bike、洗衣機與工業工具，支援 FOC 向量控制與高速 ADC。智能無弦電吉他：整合音感與壓力偵測，打造創新音樂互動體驗。電動兩輪車驅動器：結合馬達控制與動能回收，滿足新能源交通需求。電競鍵盤：支援 8k 回報率的與磁軸鍵盤，鎖定電競周邊市場。車載應用：涵蓋
More news about: 雅特力科技股份有限公司
Aug 14, 2025, 16:15 ET TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
TBS-2025. The acquisition provides for synergies across both TuHURA's therapeutic focus as well as TuHURA's antibody peptide or drug candidate (APC, ADC) technologies as we continue to assemble a diversified, late-stage immuno-oncology pipeline. We plan to advance TBS-2025 into a randomized Phase 2 trial
More news about: TuHURA Biosciences, Inc.
Aug 13, 2025, 08:00 ET BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan
population. - Backed by a globally recognized quality system and a strong track record in monoclonal antibody, ADC/XDC, biosimilar development and manufacturing, BioDlink, in partnership with Kexing BioPharm is fast-tracking access to high-quality oncology biosimilars
More news about: BioDlink Biopharm Co., Ltd.
Aug 12, 2025, 10:00 ET Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs
breast cancer (TNBC) patients previously treated with antibody-drug conjugate (ADC). This is the first overseas clinical study of 9MW2821, representing a significant step in Mabwell's global development of ADC therapeutics. The multicenter clinical study (NCT06908928)
More news about: Mabwell
Aug 12, 2025, 07:30 ET ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Aug 11, 2025, 21:36 ET Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million
tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals,
More news about: Fosun Pharma
Aug 11, 2025, 07:00 ET Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
disease.First patient dosed with Biohaven's TopoIx ADC, BHV-1530: In May 2025, the Company commenced dosing with BHV-1530, a potential first-in-class fibroblast growth factor receptor 3 (FGFR3)-directed ADC which utilizes the proprietary Topolx payload. BHV-1530
More news about: Biohaven Ltd.
Aug 07, 2025, 10:43 ET 再鼎醫藥公佈 2025年第二季度財務業績和近期公司進展
[1]收窄37%至3,420萬美元；正穩步邁向2025年第四季度實現盈利[1]的目標在2025 年 ASCO年會上公佈的 ZL-1310 (DLL3 ADC) 數據顯示，在二線廣泛期小細胞肺癌患者中，所有劑量組 (n=33) 的客觀緩解率 （ORR） 為 67%，1.6mg/kg 劑量組 (n=14) 的ORR 為 79%，且具有差異化安全性；註冊性臨床研究將於2025年下半年啟動貝瑪妥珠單抗全球 3 期
More news about: 再鼎醫藥
Aug 07, 2025, 08:00 ET Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
to efficiently deliver improved ADC cancer treatments, today announced financial results for the second quarter ended June 30, 2025, and provided recent corporate progress. "We're pleased with the progress made in Q2 to advance our ADC portfolio and remain on track
More news about: Whitehawk Therapeutics, Inc.
Aug 07, 2025, 06:45 ET Lilly reports second-quarter 2025 financial results and raises guidance
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting (
More news about: Eli Lilly and Company
Aug 07, 2025, 06:00 ET Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing to Advance Late-Stage Pipeline and Global Expansion
Phase 3 trials for thyroid eye disease; a novel PD-1/VEGF bispecific antibody in Phase 2 trials, being evaluated in combination with a TROP2 ADC; and a B7-H3 ADC in Phase 3 trial for 2L SCLC —both ADCs with strong best-in-class potential. About OrbiMed OrbiMed is a
More news about: Minghui Pharmaceutical
Aug 06, 2025, 17:46 ET Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight
& Johnson Innovative Medicine (BALVERSA), and Merck (KEYTRUDA). PADCEV (enfortumab vedotin-ejfv) is a pioneering Antibody-Drug Conjugate (ADC) that targets Nectin-4, a cell surface protein abundantly expressed in bladder cancer. Preclinical studies indicate that PADCEV exerts its anti-tumor
More news about: DelveInsight Business Research, LLP
Aug 06, 2025, 07:00 ET Compugen Reports Second Quarter 2025 Results
immune responses. At ASCO in June this year, AstraZeneca presented encouraging early data from trials evaluating rilvegostomig in combination with TROP2 ADC, Datroway, in NSCLC and in combination with chemotherapy in hepatobiliary cancer. The totality of this data along with data presented in 2024 highlight
More news about: Compugen Ltd.
Aug 05, 2025, 16:05 ET ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed
More news about: ADC Therapeutics SA
Aug 05, 2025, 08:00 ET Software and SaaS-Based Network Security Revenue to Nearly Double by 2029 to $22 Billion, According to Dell'Oro Group
telecommunications, security, networks, and data center industries, the worldwide network security spend, including firewall, SSE, traditional SWG appliance, WAF, and ADC segments, is projected to be on a steady upswing through 2029. Total network security revenue, spanning physical appliances, software, and SaaS form
More news about: Dell'Oro Group
Aug 05, 2025, 08:00 ET iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application
testing for combination effects with existing colorectal cancer therapies. In addition, IMPA™ phage engineering technology will be applied more broadly to ADC drug development, anti-cancer agent, and vaccines, as iNtRON Bio continues to strengthen our global technological competitiveness in these fields.
More news about: iNtRON Biotechnology, Inc.
Aug 05, 2025, 06:00 ET IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
Oncology (ESMO) in 4Q 2025First-in-human Phase 1 clinical efficacy and safety data from over 70 SCLC patients treated with IDE849 (DLL3 TOP1i ADC) will be provided as an Oral Presentation at the IASLC 2025 World Conference on Lung Cancer on September 7th,
More news about: IDEAYA Biosciences, Inc.
Aug 04, 2025, 01:56 ET Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
advancing the clinical development of its innovative pipeline, including ivonescimab, cadonilimab, ligufalimab (CD47), and AK146D1 (Trop2/Nectin4 bispecific ADC) through both in-house initiatives and strategic global collaborations. Our goal is to provide accessible and impactful survival benefits to patients
More news about: Akeso, Inc.
Aug 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Company. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed
More news about: ADC Therapeutics SA
Aug 01, 2025, 14:30 ET Xtalks Announces its Life Science Webinar Calendar for August 2025
Cancer Drug Discovery: A Synthetic Lethality Approach Using Integrated PlatformsAugust 12 - Radiotracers and ADC Targeting: Scientific Insights for In Vivo Validation and Clinical TransitionAugust 13 - AI in Drug Discovery
More news about: Xtalks
Aug 01, 2025, 10:00 ET Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA
(688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance from China's National Medical Products
More news about: Mabwell